Dee Anna Smith, Chief Executive Officer at Sarah Cannon Research Institute, shared a post by Sarah Cannon Research Institute, adding:
“It is with deep gratitude and admiration that we celebrate the remarkable career of my colleague and friend, Dr. Howard “Skip” Burris, who will retire as President and Chief Medical Officer of Sarah Cannon Research Institute at the end of this year.
Skip Burris, MD’s leadership has shaped the foundation of SCRI, from pioneering the first community-based phase I program to initiating more than 850 first-in-human trials that have led to transformative therapies for people facing cancer. His legacy is one of innovation, compassion, and a relentless pursuit of advancing therapies for patients. We are grateful that his guidance will continue in an advisory capacity, where he will support our relationships with biopharma partners and help steer key initiatives related to Accelero.
As we honor Dr. Burris, I am thrilled to congratulate the next generation of leaders who will carry our mission forward.
Each of these leaders brings deep expertise, a commitment to scientific excellence, and a shared passion for advancing cancer care.
Please join me in thanking Dr. Burris for his decades of service and in celebrating the exciting future ahead for SCRI.”
Quoting Sarah Cannon Research Institute‘s post:
We are honored to celebrate the extraordinary career of Dr. Howard “Skip” Burris, who will retire as President and Chief Medical Officer of Sarah Cannon Research Institute at the end of this year. We are pleased that his guidance will continue in an advisory capacity, where he will support our relationships with biopharma partners and help steer key initiatives related to Accelero.
Dr. Burris’s visionary leadership has shaped the future of cancer research—from founding the first community-based phase I program to initiating more than 850 first-in-human trials that led to FDA-approved therapies.
As we thank Dr. Burris for his decades of service, we also welcome a new chapter of leadership:
- David R. Spigel, MD, incoming President and CMO
- Melissa Johnson, incoming Chief Scientific Officer
- Erika Hamilton, MD, FASCO, incoming Chief Development Officer, Late-Phase
- Vivek Subbiah, MD, continuing as Chief, Early-Phase Drug Development
These leaders will carry forward our mission to advance cancer care through innovation, collaboration, and scientific excellence.
Read the full announcement.”